Russia Flu Diagnostic And Treatment Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Type Of Flu (Type A, Type B), By Offering (Diagnostics (Rapid Influenza Diagnostic Test, Rapid Molecular Assay, Others), Therapeutics), By Age Group (0-14 Years, 15-64 Years, >=65 Years), And By End-User (Hospital Laboratory, Outpatient Clinic, Reference Laboratory) - Forecasts From 2022 To 2027

The Russian flu diagnostic and treatment market is projected to grow at a CAGR of 6.38% throughout the forecast period and reach a market value of US$846.381 million by 2027. The market was valued at US$548.825 million in 2020.

The flu diagnostics and treatment market in Russia is poised to grow because of the availability of a highly advanced healthcare system. The Russian government ensures that free health services are available adequately to the country's citizens via Obligatory Medical Insurance (OMI). In addition, the seasonal prevalence of influenza is also projected to impact the market growth during the next five years positively. Healthcare services are mostly free throughout the country because of the compulsory state health insurance program. However, the organizational structure coupled with limited government funding further leads to an effect on affect healthcare in the country thereby, which is expected to impact the flu diagnostic and treatment market growth moderately.

Seasonal influenza cases are driving the market.

Furthermore, the continuously growing incidence of seasonal flu across the country is one of the key factors expected to supplement the market's growth throughout the forecast period and beyond. Moreover, the growing adoption of private healthcare because of the presence of state-of-the-art private healthcare is further leading to the adoption of costly treatments and services as numerous private facilities are expanding their services to people with insurance. The unavailability of the required services from the country's public health system is further leading to the high adoption of private healthcare services in the country, leading to a surge in out-of-pocket Expenditure. 

Increasing Expenditure shows continuous growth.

The continuous growth in out-of-pocket Expenditure also shows the potential for the market growth of flu diagnosis and treatment during the coming years. For instance, in Russia, the out-of-pocket Expenditure (% of current health expenditure) reached 40.485% in 2016 from 31.127% in 2006. This, in turn, is boosting the adoption of private health insurance, significantly increasing the adoption of highly advanced private healthcare services by the population, which is also projected to significantly drive the flu diagnostic and treatment market growth in the Russian Federation during the next five years.

The Russian flu diagnostic and treatment market has been segmented based on the type of flu, offering, age group, and end-user. Based on the type of flu, the market has been classified into type A and type B. By offering, the market has been segmented into diagnostics and therapeutics. By the age group, the market has been segmented based on age groups of 0-14 years, 15-64 years, and >=65 years. By the end-user, the segmentation has been done based on the hospital laboratory, outpatient clinic, and reference laboratory.

Key Developments

• November 2021 - Global flu vaccine manufacturers are losing market share in Russia. The switch to more expensive medications, like those having antigens of four virus strains, was primarily responsible for the surge.
• February 2021 - WHO was informed by the National IHR Focal Point for the Russian Federation that avian influenza A (H5N8) had been found in seven clinical samples. These are the first avian influenza A(H5N8) instances in humans that have been documented. Workers at poultry farms who took part in a response operation to contain an avian influenza A(H5N8) outbreak discovered in a poultry farm in Astrakhan Oblast in the Russian Federation provided positive clinical specimens. The State Research Centre for Virology and Biotechnology VECTOR completed the laboratory confirmation of the seven specimens (WHO H5 Reference Laboratory). Five of the seven positive cases were female and ranged in age from 29 to 60.
• May 2020 - The first Covid-19 medication, a generic version of the Japanese flu treatment Avigan, has received approval from the Russian Ministry of Health. The novel coronavirus's reproduction is intended to be disrupted by the drug affair, created by a collaboration between the Russian Direct Investment Fund and ChemRar Group. This drug has completed clinical studies.

 Impact of the COVID-19 pandemic

The COVID-19 pandemic has had a substantial impact on the market for influenza diagnostics; unfavourable changes in rules and standards, the closure of factories owing to lockdowns, and interruptions in supply chains have negatively impacted the market growth. The availability of influenza diagnostics products to end customers has also been affected by regional operations in most businesses, insufficient funding for academic and research institutions, and difficulties in delivering necessary or post-sale services because of lockdowns. In the near term, COVID-19 influenced the market for influenza diagnostic tests; however, in the long term, declining COVID-19 infection rates and patient numbers, along with rising product demand, are anticipated to drive the market share for these tests.

Segmentation

• By Type of Flu
  • Type A
  • Type B
• By Offering
  • Diagnostics
    • Rapid Influenza Diagnostic Test
    • Rapid Molecular Assay
    • Others
  • Therapeutics
• By Age Group
  • 0-14 Years
  • 15-64 Years
  • >=65 Years
• By End-User
  • Hospital Laboratory
  • Outpatient Clinic
  • Reference Laboratory